Study to Compare Efficacy and Safety of LUBT010 and Lucentis® in Patients With Neovascular AMD

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
This study is designed to compare the efficacy, safety and immunogenicity of LUBT010 with Lucentis® given as once monthly intravitreal injection in patients with neovascular age-related macular degeneration (AMD).
Epistemonikos ID: 2e4c52688331d4a648cffc778774004f41392b09
First added on: May 08, 2024